MedTrace Logo

Cardiovascular Fibrosis in Idiopathic Pulmonary Fibrosis

NCT04177251 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-10-26

No results posted yet for this study

Summary

Fibroproliferative diseases, including pulmonary, cardiac and vascular fibrosis share common pathogenetic mechanisms. Furthermore, cardiovascular comorbidities are frequently found in patients with IPF. However, the prevalence of cardiac and vascular fibrosis in patients with IPF have yet to be determined.

Main Purpose of this study is to evaluate, with non-invasive methods (echocardiogram, endothelial function and pulse wave velocity) and blood biomarkers (galectins-3, osteopontin, periostin and pro-BNP), the presence of vascular fibrosis (vascular rigidity and endothelial function) and cardiac fibrosis (prevalence of HFpEF - Heart Failure with Preserved Ejection Fraction) in patients with idiopathic pulmonary fibrosis (IPF), compared to healthy controls.

Conditions

Sponsors & Collaborators

  • San Gerardo Hospital

    lead OTHER

Principal Investigators

  • Paola Faverio, MD · Università degli Studi di Milano Bicocca - Ospedale San Gerardo

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-21
Primary Completion
2022-10-15
Completion
2022-10-15

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04177251 on ClinicalTrials.gov